10.7150/thno.66456 17
[DOI] [PMC free article] [PubMed] [Google Scholar] 139.Pangalangan J, Puma J, Tollefson M, Frates B
Teva Pharmaceutical Industries Ltd
As GLP-1s gain approvals for additional disease areas - Novo is studying semaglutide in addiction, osteoarthritis, and MASHthe companies continue extending patent protection through method-of-use claims that could sustain market exclusivity well beyond initial compound patents [40]
What to Expect During the Process While GLP-1 treatments can lead to significant weight loss, its important to approach this journey with realistic expectations and proper guidance
He wrote in his June letter to lawmakers that these drugs can cost $1,000 a month per person and that even temporary coverage could set expectations for long-term use that Louisiana simply cannot afford. The state Office of Group Benefits spends $200 million annually on GLP-1s for diabetes treatment alone and is adding people everyday, CEO Heath Williams told lawmakers at a September finance committee meeting
